Efficacy and Safety of Atezolizumab Plus Bevacizumab in Patients With Advanced <scp>NSCLC</scp> Who Received Pretreatment With <scp>EGFR</scp> ‐ <scp>TKIs</scp> ( <scp>ML41256</scp> ): A Multicenter, Prospective, Single‐Arm, Phase 2 Trial
Efficacy and Safety of Atezolizumab Plus Bevacizumab in Patients With Advanced NSCLC Who Received Pretreatment With EGFR ‐ TKIs ( ML41256 ): A Multicenter, Prospective, Single‐Arm, Phase 2 Trial
Qitao Yu, Zhehai Wang, Jian Fang, Panwen Tian et al.
Journal
Cancer Medicine
Topics
Lung Cancer Treatments and Mutations
article
Efficacy and Safety of Atezolizumab Plus Bevacizumab in Patients With Advanced NSCLC Who Received Pretreatment With EGFR ‐ TKIs ( ML41256 ): A Multicenter, Prospective, Single‐Arm, Phase 2 Trial
Qingdao University (CN), Sun Yat-sen University (CN), Peking University (CN), Sichuan University (CN), West China Hospital of Sichuan University (CN), Peking University Cancer Hospital (CN), Zhejiang Cancer Hospital (CN), Shandong Tumor Hospital (CN), Affiliated Hospital of Qingdao University (CN), Sichuan Cancer Hospital (CN), Roche (China) (CN), Sun Yat-sen University Cancer Center (CN), Tumor Hospital of Guangxi Medical University (CN), Shandong First Medical University (CN), Hangzhou Cancer Hospital (CN), State Key Laboratory of Oncology in South China